A review of the first year of Medicare coverage of erythropoietin. (Q33556073)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

title

A review of the first year of Medicare coverage of erythropoietin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference

R I Griffiths

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

N R Powe

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

J Greer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

G de Lissovoy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

G F Anderson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

P K Whelton

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

A J Watson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

P W Eggers

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

publication date

1 January 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

Health Care Financing Review

13 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

page(s)

83-102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

13 November 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193448

Recombinant human erythropoietin therapy in end stage renal failure

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193448

Recombinant erythropoietin and Medicare payment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193448

National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193448

Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4193448

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Normal reference laboratory values

21 June 2018

1 reference

12 December 2020

Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease

1 reference

12 December 2020

Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis

1 reference

12 December 2020

Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group

1 reference

12 December 2020

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

12 December 2020

1 reference

12 December 2020

Early dosing practices and effectiveness of recombinant human erythropoietin

1 reference

12 December 2020

The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group

1 reference

12 December 2020

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

1 reference

12 December 2020

Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10137799%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference